Lexeo Therapeutics Inc (LXEO) 13F Holders & Ownership Data (145 Funds, Q2 2026)

LXEO ranks #3768 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

145 institutions disclose a position in LXEO, but none treat it as a major bet — even Affinity Asset Advisors, LLC, its most concentrated holder, allocates just 1.2% of its own portfolio to it.

Essential Partners LLC has trimmed its LXEO position for two straight quarters, cutting it by $1.9K while still holding $811.0.

LXEO is down 2.5% today, but institutions show net buying of $59.1M this quarter — a divergence between today's price move and the underlying institutional flow.

LXEO reported a net loss of $100.0M in its latest fiscal year.

• Not yet profitable — net loss of $100.0M in the latest fiscal year
• Net income declined year over year, from -$98.3M to -$100.0M
• Operating cash flow was negative, using $98.6M in cash
• Current ratio of 11.21x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.09x equity — within a conventional range